The purpose of this randomized clinical trial is to compare the efficacy and safety of intraoperative mitomycin C(MMC) combined with limbal conjunctival autograft(LCAG) or conjunctival autograft(CAG) for recurrent pterygium surgery. The investigators will also evaluate particular risk factors related to pterygium recurrence
Intraoperative mitomycin C after pterygium excision is widely used to prevent recurrce of recurrent pterygium. Conjunctival autograft with or without limbal tissue used to cover the bare sclera will efficiently reduce postoperative longstanding epithelial defect. Patients with recurrent pterygium will be randomly assigned to undertake pterygium excision followed by intraoperative mitomycin C with conjunctival autograft or limbal conjunctival autograft .The patients will be followed at least 12 months. Corneal recurrence is considered as a fibrovascular ingrowth beyond the limbus with conjunctival drag in the area of previous pterygium excision.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
116
Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China
RECRUITINGRecurrence of pterygium
Time frame: One year
Visual acuity
Time frame: One year
Healing time of corneal epithelium
Time frame: Four weeks
Healing time of conjunctival epithelium
Time frame: Four weeks
Postoperative complications
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.